All In MedTech

Device Trial Radar · NCT07073950

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With Chronic Obstructive Pulmonary Disease and Hyperinflation

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Nov 24, 2025

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
AstraZenecaNot on our public-company list
Sponsor type
Industry
Collaborators
Parexel
First posted
Jul 20, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.

Conditions

  • Chronic Obstructive Pulmonary Disease
  • Hyperinflation

Interventions

  • Budesonide/Glycopyrronium/Formoterol FumarateDrug

    BGF will be administered as 2 inhalations via oral route of administration

  • PlaceboDrug

    Matching placebo will be administered as 2 inhalations via oral route of administration

  • Metered dose inhalerDevice

    Participants will receive BGF and matching placebo via metered dose inhaler in treatment periods of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in left ventricular end diastolic volume indexed by body surface area (LVEDVi) measured by magnetic resonance imaging (MRI)Time frame: Up to 3 weeks

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Ahrensburg, Germany · Recruiting

  • Research Site

    Berlin, Germany · Recruiting

  • Research Site

    Frankfurt, Germany · Recruiting

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.